{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 25 of 52', '7.2.2', 'Exclusion criteria', 'Patients who meet any of the following criteria will be excluded from this study:', '1. Patient has loose (mushy) or watery stools for > 25% of their bowel movements (BMs) during', 'the 12 weeks before Screening or during the Screening and Pre-treatment Periods.', '2.', 'Patient has a history of cathartic colon, laxative, or enema abuse.', '3. Patient has a history of ischemic colitis.', '4. Patient has a history of pelvic floor dysfunction.', '5.', 'Patient has a history of bariatric surgery for the treatment of obesity.', '6. Patient has a history of surgery to remove a segment of the gastrointestinal (GI) tract at any', 'time before the Screening Visit.', '7. Patient has any history of myopathy, rhabdomyolysis, chronic myalgia, or familial history of', 'hereditary muscular disorders.', '8. Patient has been diagnosed with or has a family history of familial adenomatous polyposis,', 'hereditary nonpolyposis colorectal cancer, or any other form of familial colorectal cancer.', '9. Patient currently has any structural abnormality of the GI tract or a disease or condition that', 'can affect GI motility, or any unexplained and clinically significant symptoms such as lower GI', 'bleeding, rectal bleeding, heme-positive stool, iron-deficiency anemia, weight loss, or', 'systemic signs of infection.', '10. Patient has had any previous surgery involving the abdomen, pelvis, or retroperitoneal region', 'during the last 12 months prior to Screening, with the exclusion of laparoscopic gallbladder', 'surgery or appendix removal.', '11. Patient has a history of diverticulitis or any chronic condition that could be associated with', 'abdominal pain or discomfort and could confound the assessments in the study (e.g.', 'inflammatory bowel disease, chronic pancreatitis, polycystic kidney disease, ovarian cysts,', 'endometriosis, or lactose intolerance).', '12. Patient has history of severe renal insufficiency defined as an actual or estimated glomerular', 'filtration rate of < 30 mL/min/1.73 m\u00b2 within the 6 months prior to Screening Visit.', '13. Patient has any history of a medical condition or a concomitant medical condition that, in the', \"opinion of the investigator, would compromise the patient's ability to complete the study\", 'safely or could confound the assessments in this study (e.g. uncontrolled hypothyroidism).', '14. Patient is known to have elevated liver enzyme levels (aspartate aminotransferase [AST],', 'alanine aminotransferase [ALT], alkaline phosphatase [ALP]) or creatine kinase levels that are', '1.5 times the upper limit of normal (ULN) that have not been resolved within the 4 weeks', 'prior to consent and/or these elevated levels are present at the Screening Visit laboratory', 'assessment.', '15. Patient has any abnormal laboratory results, electrocardiogram (ECG) findings, or physical', 'examination findings deemed clinically significant by the investigator during the Screening', 'Period.', '16. Within 14 days prior to the Screening Visit, patient has used concomitant medications that', 'are: (1) moderate-to-strong inhibitors of cytochrome P450 3A (CYP3A) and/or organ anion', 'transporting polypeptide (OATP)1B1 (e.g. cyclosporine, verapamil, dronedarone, diltiazem,', 'amiodarone, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin,', 'telithromycin, human immunodeficiency virus protease inhibitors, boceprevir, telaprevir,', 'nefazodone, erythromycin, cobicistat-containing products); (2) other concomitant', 'medications that are excluded from the lovastatin label (e.g. rifampin, colchicine, ranolazine);', 'or (3) metformin or GLP-1 agonists. Patients should not take any of these concomitant']['Date: June 30, 2020', 'Version: 8.0', 'Page: 26 of 52', 'medications during the treatment phase of the study without contacting the investigator.', '17. Patient has hypersensitivity to statins; or has used any statins, fibrates, > 1 g/day of niacin, or', 'gemfibrozil within the 3 months prior to the Screening Visit.', '18. Patient reports current chronic or frequent use of drugs known to cause constipation (e.g.', 'narcotics) for the 3 months prior to Screening.', '19. Patient has taken over-the-counter IBS treatments (e.g. laxatives) or proton pump inhibitors', 'within 3 days prior to the Screening Visit.', '20. Certain drugs used for the treatment of IBS (e.g. low dose tricyclic antidepressants) may be', 'allowed at the discretion of the Medical Monitor provided the patient remains on a stable', 'dose for one month prior to the Screening Visit and throughout the study with the exception', 'of tegaserod, lubiprostone, linaclotide, metoclopramide, prucalopride, domperidone,', 'plecanatide, CandiBactin, Atrantil, Allimax/Allimed within 2 weeks prior to the Screening Visit', 'or antibiotics within 2 months prior to the Screening Visit.', '21. Patient has used an opioid chronically or frequently within the 3 months prior to the', 'Screening Visit and for the duration of the study.', '22. Patient is currently enrolled in, or plans to enroll in, another clinical study or has used any', 'investigational drug or device within 1 month before signing the ICF through the completion', 'of the study.', '23. Patient has previously participated in a SYN-010 study.', '24. Patient has a history of alcohol or drug abuse within the 12 months prior to the Screening', 'Visit.', '7.3', 'Excluded therapies and medications, previous and concomitant', 'Prior use of SYN-010.', 'Concurrent use of another investigational drug or device therapy (i.e. outside of study', 'treatment) during or within 4 weeks of trial entry (signing of the informed consent form).', 'Major surgery within 30 days prior to start of study drug.', '7.4', 'Removal of patients from therapy or assessment', 'The investigator may discontinue treating a patient with a study drug or withdraw the patient from', 'the study at any time for safety or administrative reasons. The patient may decide to discontinue', 'study drug or withdraw from the study at any time for any reason. The reason for discontinuation', 'must be documented.', '7.5', 'Withdrawal of patients from the study', 'Patients must be withdrawn from the trial (treatment and procedures) for the following reasons:', 'Patient withdraws consent from study treatment and study procedures. A patient must be', 'removed from the trial at his/her own request or at the request of his/her legally acceptable', 'representative. At any time during the trial and without giving reasons, a patient may', 'decline to participate further. The patient will not suffer any disadvantage as a result.', 'Patient is lost to follow-up.', 'Death.', 'Pregnancy. Lovastatin is a pregnancy Category X drug and should not be taken during', 'pregnancy. Female subjects who become pregnancy must immediately discontinue taking', 'the study drug. Subjects will be instructed that known or suspected pregnancy occurring']\n\n###\n\n", "completion": "END"}